摘要
目的研究孟鲁司特联合布地奈德治疗儿童哮喘的疗效及安全性。方法选择支气管哮喘患儿97例，按就诊顺序随机分为观察组47例，对照组50例。对照组患儿常规吸入布地奈德气雾剂200鹇，1次／d，共治疗28周。观察组患儿常规吸入布地奈德气雾剂治疗的同时，加用孟鲁司特钠片，每次4mg,每晚睡前口服1次，共治疗28周。治疗结束后评价两组患儿肺功能、嗜酸细胞计数、血清IgE，并监测安全性指标，进行疗效判定。结果临床总有效率观察组优于对照组（P〈0．01）；两组治疗前后肺功能、IsE水平、嗜酸细胞计数均有显著改善（均P〈0．05），且观察组优于对照组（均P〈0．05）。安全性指标均无异常变化。结论孟鲁司特钠联合布地奈德对于儿童哮喘疗效肯定，依从性好，无明显不良反应，安全可靠。
Objective To study the efficacy and safety of montelukast combined with Budesonide in treatment of childhood asthma. Methods 97 patients with bronchial asthma,GINA guidelines meet the diagnostic criteria for bronchial asthma in children were selected. 97 cases were divided into two groups, control group of 50 patients 47 patients in observation group. Children in normal control group inhaled budesonide 200txg, 1/d,a total of 28 weeks of treatment. Routine observation group patients inhaled budesonide treatment at the same time, plus montelukast sodium tablets, each 4rag, oral administration of a second before going to bed every night, a total of 28 weeks of treatment. After treatment, patients were evaluated the efficacy observed indicators for the treatment of lung function before and after treatment,eosinophil counts, serum IgE, and to monitor the safety index. Results The clinical total effective rate in observation group was better than the control group（P 〈0.01 ） ;lung function before and after treatment in beth groups, IgE levels, eosinophil counts were significantly improved（ all P 〈 0. 05）, and the observation group was better than the control group （ all P 〈 0. 05 ）. The monitoring of safety indicators, there was no abnormal changes. Conclusion Montelukast combined with budesonide for asthma in children was effective and good compliance, no significant side effects, safe and reliable, could be used as first-line choice in treatment of asthma in children, was worthy in extensive promotion.
出处
《中国基层医药》
CAS
2011年第22期3045-3046,共2页
Chinese Journal of Primary Medicine and Pharmacy
